|
Lymphoma, T-Cell
|
D016399 |
[A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.
] |
|
Lymphoma, T-Cell, Cutaneous
|
D016410 |
[A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.
] |
|
Lymphoma, T-Cell, Peripheral
|
D016411 |
[A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.
] |
|
Lymphomatoid Granulomatosis
|
D008230 |
[An angiocentric and angiodestructive lymphoproliferative disorder primarily involving the lungs. It is caused by an Epstein-Barr virus-induced transformation of the B-cells, in a T-cell rich environment. Clinically and pathologically it resembles EXTRANODAL NK-T-CELL LYMPHOMA.
] |
|
Lymphomatoid Papulosis
|
D017731 |
[Clinically benign, histologically malignant, recurrent cutaneous T-cell lymphoproliferative disorder characterized by an infiltration of large atypical cells surrounded by inflammatory cells. The atypical cells resemble REED-STERNBERG CELLS of HODGKIN DISEASE or the malignant cells of CUTANEOUS T-CELL LYMPHOMA. In some cases, lymphomatoid papulosis progresses to lymphomatous conditions including MYCOSIS FUNGOIDES; HODGKIN DISEASE; CUTANEOUS T-CELL LYMPHOMA; or ANAPLASTIC LARGE-CELL LYMPHOMA.
] |
|
Lymphopenia
|
D008231 |
[Reduction in the number of lymphocytes.
] |
|
Lymphopoiesis
|
D038041 |
[Formation of LYMPHOCYTES and PLASMA CELLS from the lymphoid stem cells which develop from the pluripotent HEMATOPOIETIC STEM CELLS in the BONE MARROW. These lymphoid stem cells differentiate into T-LYMPHOCYTES; B-LYMPHOCYTES; PLASMA CELLS; or NK-cells (KILLER CELLS, NATURAL) depending on the organ or tissues (LYMPHOID TISSUE) to which they migrate.
] |
|
Lymphoproliferative Disorders
|
D008232 |
[Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
] |
|
Lymphoscintigraphy
|
D061305 |
[Radionuclide imaging of the LYMPHATIC SYSTEM.
] |
|
Lymphotoxin alpha1, beta2 Heterotrimer
|
D053361 |
[A heterotrimer complex consisting of one molecule of LYMPHOTOXIN-ALPHA and two molecules of the LYMPHOTOXIN-BETA. It is anchored to the cell surface via the transmembrane domains of the lymphotoxin-beta component and has specificity for the LYMPHOTOXIN BETA RECEPTOR. The lymphotoxin alpha1, beta2 heterotrimer plays a role in regulating lymphoid ORGANOGENESIS and the differentiation of certain subsets of NATURAL KILLER CELLS.
] |
|
Lymphotoxin beta Receptor
|
D053259 |
[A member of the tumor necrosis factor receptor superfamily. It has specificity for LYMPHOTOXIN ALPHA1, BETA2 HETEROTRIMER and TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14. The receptor plays a role in regulating lymphoid ORGANOGENESIS and the differentiation of certain subsets of NATURAL KILLER T-CELLS. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
] |
|
Lymphotoxin-alpha
|
D008233 |
[A tumor necrosis factor family member that is released by activated LYMPHOCYTES. Soluble lymphotoxin is specific for TUMOR NECROSIS FACTOR RECEPTOR TYPE I; TUMOR NECROSIS FACTOR RECEPTOR TYPE II; and TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14. Lymphotoxin-alpha can form a membrane-bound heterodimer with LYMPHOTOXIN-BETA that has specificity for the LYMPHOTOXIN BETA RECEPTOR.
] |
|
Lymphotoxin-beta
|
D053308 |
[A membrane-bound tumor necrosis family member found primarily on LYMPHOCYTES. It can form a heterotrimer (LYMPHOTOXIN ALPHA1, BETA2 HETEROTRIMER) with the soluble ligand LYMPHOTOXIN-ALPHA and anchor it to the cell surface. The membrane-bound complex is specific for the LYMPHOTOXIN BETA receptor.
] |
|
Lynch Syndrome II
|
D055847 |
[Hereditary nonpolyposis colorectal neoplasms associated with other malignancies, more commonly of ovarian or uterine origin. When also associated with SEBACEOUS GLAND NEOPLASMS, it is called MUIR-TORRE SYNDROME.
] |
|
Lynestrenol
|
D008234 |
[A synthetic progestational hormone used often in mixtures with estrogens as an oral contraceptive (CONTRACEPTIVES, ORAL).
] |
|
Lyngbya
|
D000083582 |
[A unicellular, photosynthetic genus of CYANOBACTERIA belonging to the family Oscillatoriaceae. It is a known cause of seaweed dermatitis and also Ciguatera poisoning when ingested.
] |
|
Lyngbya Toxins
|
D008235 |
[Toxins isolated from any species of the seaweed LYNGBYA or similar chemicals from other sources, including mollusks and micro-organisms. These have been found to be potent tumor promoters. They are biosynthesized from TRYPTOPHAN; VALINE; and METHIONINE nonribosomally (PEPTIDE BIOSYNTHESIS, NUCLEIC ACID-INDEPENDENT).
] |
|
Lynx
|
D046008 |
[A genus in the family FELIDAE comprising felines with long legs, ear tufts, and a short tail.
] |
|
Lypressin
|
D008236 |
[The porcine antidiuretic hormone (VASOPRESSINS). It is a cyclic nonapeptide that differs from ARG-VASOPRESSIN by one amino acid, containing a LYSINE at residue 8 instead of an ARGININE. Lys-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.
] |
|
Lysergic Acid
|
D008237 |
|
